Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABVC

ABVC - ABVC Biopharma Stock Price, Fair Value and News

1.20USD-0.01 (-0.83%)Market Closed
Watchlist

Market Summary

USD1.20-0.01
Market Closed
-0.83%

ABVC Stock Price

View Fullscreen

ABVC RSI Chart

ABVC Valuation

Market Cap

8.7M

Price/Earnings (Trailing)

-0.71

Price/Sales (Trailing)

16.54

EV/EBITDA

-0.8

Price/Free Cashflow

-2.17

ABVC Price/Sales (Trailing)

ABVC Profitability

Operating Margin

24.64%

EBT Margin

-1942.39%

Return on Equity

-134.82%

Return on Assets

-73.95%

Free Cashflow Yield

-46.13%

ABVC Fundamentals

ABVC Revenue

Revenue (TTM)

568.3K

Rev. Growth (Yr)

-62.42%

Rev. Growth (Qtr)

160.01%

ABVC Earnings

Earnings (TTM)

-12.3M

Earnings Growth (Yr)

10.46%

Earnings Growth (Qtr)

-46.57%

Breaking Down ABVC Revenue

Last 7 days

-3.8%

Last 30 days

-11.2%

Last 90 days

-18.1%

Trailing 12 Months

-83.1%

How does ABVC drawdown profile look like?

ABVC Financial Health

Current Ratio

0.46

ABVC Investor Care

Shares Dilution (1Y)

121.62%

Diluted EPS (TTM)

1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20210000
2020568.3K000
2019000701.7K
20180000
20170000
20160000
2015003.4K0
20140000
201326.9K7.8K7.8K0
20120024.9K29.9K
20110000
201000434.1K0

Which funds bought or sold ABVC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-21,000
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
74.19
15,288
31,503
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
48.72
12,553
31,607
-%
Feb 13, 2024
RENAISSANCE TECHNOLOGIES LLC
new
-
42,000
42,000
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
unchanged
-
2,337
22,596
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
reduced
-80.64
-2,434
670
-%
Feb 12, 2024
JPMORGAN CHASE & CO
sold off
-100
-2.00
-
-%
Feb 09, 2024
WELLS FARGO & COMPANY/MN
added
11.11
4.00
23.00
-%

1–10 of 12

Are Funds Buying or Selling ABVC?

Are funds buying ABVC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABVC
No. of Funds

Unveiling ABVC Biopharma's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
lind global fund ii lp
9.9%
770,000
SC 13G/A
Aug 07, 2023
lind global fund ii lp
9.9%
385,000
SC 13G
Jul 12, 2022
jiang shuling
24.5%
7,908,805
SC 13D

Recent SEC filings of ABVC Biopharma

View All Filings
Date Filed Form Type Document
Feb 29, 2024
8-K/A
Current Report
Feb 29, 2024
8-K/A
Current Report
Feb 16, 2024
S-1/A
Initial Public Offering
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
S-1/A
Initial Public Offering
Feb 08, 2024
8-K
Current Report
Jan 26, 2024
8-K/A
Current Report
Jan 17, 2024
8-K/A
Current Report
Jan 17, 2024
8-K
Current Report
Jan 17, 2024
8-K
Current Report

Peers (Alternatives to ABVC Biopharma)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.7B
396.6M
-2.06% 34.31%
-14.57
19.42
425.83% 18.94%
6.3B
-
-3.85% 226.12%
-10.06
60.35
54.84% -25.61%
4.5B
240.7M
-19.08% -10.99%
-15.05
18.56
-1.03% -92.09%
4.0B
726.4M
-12.60% 32.37%
-64.55
5.45
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

ABVC Biopharma News

Latest updates
AmericanBankingNEWS25 hours ago
CNN21 Feb 202412:04 am
MarketWatch03 Jan 202408:00 am
Pharmaceutical Technology3 months ago

ABVC Biopharma Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue160.0%15,8846,109128,27285,27142,269312,86025,66013,4301,20029,78858,37786,965115,55397,17078,78699,962197,733191,782212,242194,779177,316
Cost Of Revenue-59.4%29,61472,98160,236265,41110,7418,3671,8962,8023936461,2451,9028,6194,2363,9592,4892,79713,3521,499182,424537
Gross Profit79.5%-13,730-66,87268,036323,58331,528304,49323,764-40,59598,60630,795261,90560,291106,934222,27774,82797,473194,936178,430210,743-179,444210
Operating Expenses0.7%2,141,1432,126,9701,974,2203,456,5733,747,3692,351,3536,242,4856,406,5592,069,1602,066,3101,514,6504,910,9111,396,7001,416,2901,246,2041,221,2561,310,558667,238941,3091,010,203396,495
  S&GA Expenses-14.8%1,182,0931,386,7881,272,75267,4903,216,1461,592,8311,191,0781,766,8361,579,9961,231,6921,167,5951,080,8571,262,1991,277,1331,152,889937,5281,041,319571,669510,803375,405334,406
  R&D Expenses-72.5%141,310514,442334,9791,495,788305,483532,782359,404260,188263,424358,878121,315183,285134,501139,08292,790269,589269,23987,769421,956629,39954,514
EBITDA Margin13.6%-16.69-19.33-19.15-26.74-31.17-28.14-28.17-19.31-17.58-17.99-18.09-18.25---------
Interest Expenses962.0%1,218,624114,75256,663134,461126,53614,75818,213-24,36738,67782,671130,229116,67916,311140,525131,517107,474111,968132,686129,886116,769122,326
Income Taxes-101.2%-99981,695-962,8744,222-82,451-86,8671,011,279-75,667-59,564-51,024-86,405-44,735-48,644-40,568-27,25348,555-40,798-57,545-124,855-69,075
Earnings Before Taxes-50.8%-3,369,079-2,233,530-1,897,230-3,538,028-3,772,302-2,029,784-6,174,482-5,890,049-1,961,911-2,112,520-1,246,347-5,055,539-2,175,866-2,232,701-1,349,830-1,143,038-1,281,130-655,251-930,862-4,052,423-756,375
EBT Margin3.5%-19.42-20.13-19.77-27.30-31.44-28.25-28.40-19.73-18.26-18.64-18.85-19.03---------
Net Income-46.6%-3,317,516-2,263,511-1,823,695-4,863,938-3,704,864-1,858,997-5,995,440-7,858,150-1,806,488-2,052,956-1,195,323-4,969,134-2,131,131-2,184,057-1,309,262-1,115,785-1,329,685-614,453-873,317-3,927,568-687,300
Net Income Margin3.1%-21.59-22.27-21.56-28.90-34.17-30.83-31.17-22.72-17.64-18.21-18.44-18.64---------
Free Cashflow-51.0%-1,359,014-899,916-1,497,722-461,158-518,061-3,451,387-3,087,477-2,524,616-2,216,025-1,444,004-1,413,074-2,188,046---------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets78.0%16,5929,32010,7359,58010,48113,78312,06713,69812,3558,94510,52611,6076,5296,4326,6656,9287,4057,1407,4505,9402,594
  Current Assets17.1%2,4942,1293,4802,9872,9039,7897,9887,6547,1113,6285,2056,1731,1781,6058028781,7081,2341,5275662,594
    Cash Equivalents1029.0%1,12199.001,1351,3921,9703,5993,4336,5654,4501,6573,3335,0011524061401601,052556997243217
  Inventory-----20.0022.0023.0026.0060.00--------258*521*1.00-
  Net PPE1309.4%7,954564572574567597599526528512505515506508505521514529548510-
Liabilities-22.3%7,5309,6879,0006,3434,7874,6024,7054,8284,7658,4298,7978,9457,7217,8767,8377,0536,67510,28212,97711,2815,043
  Current Liabilities-7.1%5,3635,7735,0755,5443,8943,6463,6643,6923,4394,3764,6664,8446,0467,5747,6556,8145,87810,10812,43510,9884,479
  Short Term Borrowings-853--1,894---1,640-------------
Shareholder's Equity568.1%9,1001,3621,6703,0995,6939,1817,3618,8447,5905161,7292,66229,94928,22328,22328,18073018,68815,68114,98414,978
  Retained Earnings-5.6%-62,309-58,991-56,728-54,904-50,040-46,335-44,476-38,481-30,548-28,742-26,770-25,642-20,794-18,948-17,098-15,851-14,773-13,558-13,001-12,209-16,571
  Additional Paid-In Capital18.5%80,66268,07868,04867,93766,49466,24062,57958,11449,71641,00240,75240,75229,94928,22328,22328,18028,18018,68815,68114,98413,909
Shares Outstanding45.8%4,8233,3083,3083,2863,2583,1312,96825,0542,5042,4422,4422,4421,949--------
Minority Interest-410.9%-38.2612.0064.00138-225-153-65.4927.00-1,004-924-843-776-655-370-35.5826.0064.00179236318-
Float------18,852---16,488---73,262-------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-51.0%-1,358-899-1,497-461-513-3,429-2,994-2,524-2,216-1,444-1,413-2,188-328-1,416-630-1,495-242-796-599268-210
  Share Based Compensation262.2%8182263661,8932262264,6924,3802264762263,14799975*525*-1676.008.009.005.008.00
Cashflow From Investing-Infinity%-73.78---83.29-1,523-22.03-93.22427-810-140-281107-365---218*-14.10-3.17-17.80-470205
Cashflow From Financing5344.4%1,657-31.592,207-253604--4,2535,817-11642.006,8694441,6456106047523581,374230-144

ABVC Income Statement

2023-09-30
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenues$ 15,884$ 42,269$ 150,265$ 380,789
Cost of revenues29,61410,741162,83121,004
Gross (loss) profit(13,730)31,528(12,566)359,785
Operating expenses    
Selling, general and administrative expenses1,182,0933,216,1463,841,6336,000,055
Research and development expenses141,310305,483990,7311,197,669
Stock-based compensation817,740225,7401,409,9695,143,483
Total operating expenses2,141,1433,747,3696,242,33312,341,207
Loss from operations(2,154,873)(3,715,841)(6,254,899)(11,981,422)
Other income (expense)    
Interest income40,24648,164147,998127,354
Interest expense(1,218,624)(126,536)(1,390,039)(159,507)
Operating sublease income(3,000)21,59753,90078,523
Gain/Loss on foreign exchange changes(25,059)(177)(55,625)17,865
Other (expense) income(7,769)491(1,174)(59,381)
Total other (expense) income(1,214,206)(56,461)(1,244,940)4,854
Loss before income tax(3,369,079)(3,772,302)(7,499,839)(11,976,568)
Provision for (benefit from) income tax(999)4,22280,696(165,096)
Net loss(3,368,080)(3,776,524)(7,580,535)(11,811,472)
Net loss attributable to noncontrolling interests(50,564)(71,660)(175,813)(252,171)
Net loss attributed to ABVC and subsidiaries(3,317,516)(3,704,864)(7,404,722)(11,559,301)
Foreign currency translation adjustment(15,082)(190,019)1,995(426,579)
Comprehensive loss$ (3,332,598)$ (3,894,883)$ (7,402,727)$ (11,985,880)
Net loss per share:    
Basic (in Dollars per share)$ (0.82)$ (1.14)$ (2.08)$ (3.71)
Weighted average shares used in computing net loss per share of common stock(1):    
Basic (in Shares)[1]4,055,3453,257,9123,555,4743,119,795
[1]Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.

ABVC Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 500,069$ 85,265
Restricted cash620,8681,306,463
Accounts receivable, net1,53098,325
Short-term Investment68,52175,797
Prepaid expenses and other current assets143,127150,235
Total Current Assets2,493,5342,987,247
Property and equipment, net7,953,936573,978
Operating lease right-of-use assets899,8171,161,141
Long-term investments2,677,395842,070
Deferred tax assets34,256117,110
Prepaid expenses – non-current128,898135,135
Security deposits44,25958,838
Prepayment for long-term investments1,429,0162,838,578
Total Assets16,591,5079,579,574
Current Liabilities  
Short-term bank loans852,5001,893,750
Accrued expenses and other current liabilities3,558,2132,909,587
Contract liabilities79,50110,985
Operating lease liabilities – current portion392,666369,314
Total Current Liabilities5,363,0765,543,628
Tenant security deposit5,6807,980
Operating lease liability – non-current portion507,151791,827
Convertible notes payable – third parties1,654,004
Total Liabilities7,529,9116,343,435
COMMITMENTS AND CONTINGENCIES
Equity  
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding
Common stock, $0.001 par value, 10,000,000 authorized, 4,823,043 and 3,286,190 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively(1)[1]4,8233,286
Additional paid-in capital80,662,29067,937,050
Stock subscription receivable(677,220)(1,354,440)
Accumulated deficit(62,309,161)(54,904,439)
Accumulated other comprehensive income519,123517,128
Treasury stock(9,100,000)(9,100,000)
Total Stockholders’ Equity9,099,8553,098,585
Noncontrolling interest(38,259)137,554
Total Equity9,061,5963,236,139
Total Liabilities and Equity16,591,5079,579,574
Related Party  
Current Assets  
Accounts receivable – related parties, net624,373757,343
Due from related party – current535,046513,819
Due from related parties – non-current930,396865,477
Current Liabilities  
Due to related parties$ 480,196$ 359,992
[1]Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.
ABVC
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
 WEBSITEwww.abvcpharma.com
 EMPLOYEES19

ABVC Biopharma Frequently Asked Questions


What is the ticker symbol for ABVC Biopharma? What does ABVC stand for in stocks?

ABVC is the stock ticker symbol of ABVC Biopharma. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ABVC Biopharma (ABVC)?

As of Fri Mar 01 2024, market cap of ABVC Biopharma is 8.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers. The fair value of ABVC Biopharma is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ABVC Biopharma is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABVC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ABVC Biopharma a good stock to buy?

The fair value guage provides a quick view whether ABVC is over valued or under valued. Whether ABVC Biopharma is cheap or expensive depends on the assumptions which impact ABVC Biopharma's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABVC.

What is ABVC Biopharma's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 01 2024, ABVC's PE ratio (Price to Earnings) is -0.71 and Price to Sales (PS) ratio is 16.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABVC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ABVC Biopharma's stock?

In the past 10 years, ABVC Biopharma has provided -0.534 (multiply by 100 for percentage) rate of return.